Environment &
Food & Beverage
Cosmetics
Life Sciences
Metal & Mining Industry
Petrochemical & General Chemistry
Automotive Related & Interior Materials
InertSearch (Application Library)
Index
Application
LC
Micro GC
Document No. Index
LB201 - 300 of Application List
| No. | Description | Column |
|---|---|---|
| LB201 | Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-3 |
| LB202 | Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil Tablets) | Inertsil ODS-3 |
| LB203 | Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil Tablets) | Inertsil ODS-3 |
| LB204 | Analysis of Metformin hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Metformin hydrochloride Tablets) | InertSustain C18 |
| LB205 | Analysis of Paroxetine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Paroxetine hydrochloride Tablets) | Inertsil TMS |
| LB206 | Analysis of Paroxetine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) | Inertsil TMS |
| LB207 | Analysis of Montelukast sodium | InertSustain Phenyl |
| LB208 | Analysis of Montelukast sodium (Oxidative degradation products) | InertSustain Phenyl |
| LB209 | Analysis of Pioglitazone hydrochloride (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB210 | Analysis of Pioglitazone hydrochloride (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB211 | Analysis of 2 kinds of Aldehydes (InertSustain C18) (Directed by Pre-Column Method with DNPH) | InertSustain C18 |
| LB212 | Analysis of 2 kinds of Aldehydes (Inersil ODS-4) (Directed by Pre-Column Method with DNPH) | Inertsil ODS-4 |
| LB213 | Analysis of 2 kinds of Aldehydes (Inersil ODS-3) (Directed by Pre-Column Method with DNPH) | Inertsil ODS-3 |
| LB214 | Analysis of 2 kinds of Aldehydes (Inersil ODS-2) (Directed by Pre-Column Method with DNPH) | Inertsil ODS-2 |
| LB215 | Analysis of 2 kinds of Aldehydes (Inersil ODS) (Directed by Pre-Column Method with DNPH) | Inertsil ODS |
| LB216 | Analysis of 2 kinds of Aldehydes (Inersil ODS-SP) (Directed by Pre-Column Method with DNPH) | Inertsil ODS-SP |
| LB217 | Analysis of 2 kinds of Aldehydes (Inersil ODS-P) (Directed by Pre-Column Method with DNPH) | Inertsil ODS-P |
| LB218 | Analysis of Diquat and Paraquat | Inertsil WP300 SIL |
| LB219 | Analysis of Amino acid (post-column ninhydrin) | # 2619PH |
| LB220 | Analysis of Amino acid (post-column OPA) | # 2619PH |
| LB221 | Analysis of Glutamic acid (post-column ninhydrin) | # 2619PH |
| LB222 | Analysis of Butenafine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 HP |
| LB223 | Analysis of Cilnidipine (Under the Condition of the Japanese Pharmacopoeia, Cilnidipine Tablets) | Inertsil ODS-4 |
| LB224 | Analysis of Tocopherol (InertSuatin C18) (Under the Condition of the Japanese Pharmaceutical Codex) | InertSustain C18 |
| LB225 | Analysis of Tocopherol (Inertsil ODS-4) | Inertsil ODS-4 |
| LB226 | Analysis of Tocopherol (Inertsil ODS-3) | Inertsil ODS-3 |
| LB227 | Analysis of Tocopherol (Inertsil ODS-2) | Inertsil ODS-2 |
| LB228 | Analysis of Polyvinyl alcohol, Polyethyleneglycol and Graft copolymer (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), (3) Acetic acid) | InertSustain C18 |
| LB230 | Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) | InertSustainSwift C18 HP |
| LB231 | Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) | InertSustainSwift C18 HP |
| LB232 | Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) | InertSustainSwift C18 HP |
| LB233 | Analysis of Amino acids | InertSustainSwift C18 |
| LB234 | Analysis of Amino acids | InertSustainSwift C18 |
| LB235 | Analysis of Preservatives and Sweetener (InertSustain Phenylhexyl) | InertSustain Phenylhexyl |
| LB236 | Analysis of Preservatives and Sweetener (InertSustainSwift C18) | InertSustainSwift C18 |
| LB237 | Analysis of Preservatives and Sweetener (InertSustain C18) | InertSustain C18 |
| LB238 | Analysis of Preservatives and Sweetener (InertSustain Phenylhexyl) | InertSustain Phenylhexyl |
| LB239 | Analysis of Preservatives and Sweetener (InertSustainSwift C18) | InertSustainSwift C18 |
| LB240 | Analysis of Preservatives and Sweetener (InertSustain Phenyl) | InertSustain Phenyl |
| LB241 | Analysis of Preservatives and Sweetener (InertSustain C18) | InertSustain C18 |
| LB242 | Analysis of Preservatives and Sweetener (Inertsil Ph) | Inertsil Ph |
| LB243 | Analysis of Acarbose (Under the Condition of the Japanese Pharmacopoeia, Acarbose Tablets) | Inertsil WP300 C18 |
| LB245 | Analysis of L-Carbocisteine (Under the Condition of the Japanese Pharmacopoeia, L-Carbocisteine Tablets) | Inertsil ODS-4 |
| LB246 | Analysis of L-Carbocisteine (Under the Condition of the Japanese Pharmacopoeia, L-Carbocisteine Tablets) | Inertsil ODS-4 |
| LB247 | Analysis of Terbinafine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Terbinafine hydrochloride Cream) | InertSustainSwift C18 |
| LB248 | Analysis of Organic electroluminescence materials | Inertsil ODS-3V |
| LB249 | Analysis of Organic electroluminescence materials | Inertsil ODS-3V |
| LB250 | Analysis of Azelnidipine (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-4 |
| LB251 | Analysis of Quetiapine fumarate (Under the Condition of the Japanese Pharmacopoeia, Quetiapine fumarate Tablets) | Inertsil C8-4 |
| LB252 | Analysis of Glimepiride | Inertsil Diol |
| LB253 | Analysis of Tranilast (Under the Condition of the Japanese Pharmacopoeia, Tranilast Capsules) | InertSustain C18 |
| LB254 | Analysis of Brotizolam (Under the Condition of the Japanese Pharmacopoeia, Brotizolam Tablets) | Inertsil WP300 C18 |
| LB255 | Analysis of Pullulan | Inertsil WP300 Diol + Inertsil Diol |
| LB256 | Analysis of Nucleobase (InertSustain C18) | InertSustain C18 |
| LB257 | Analysis of Nucleobase (InertSustain Phenyl) | InertSustain Phenyl |
| LB258 | Analysis of Tetracyclines | InertSustain C18 |
| LB259 | Analysis of Tryptic digest of proteins | MonoCap C18 High Resolution 2000 |
| LB260 | Analysis of Chlorophenol | InertSustain C18 HP |
| LB261 | Analysis of 18 Drugs | Inertsil ODS-3 |
| LB262 | Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) | InertSustain C8 |
| LB263 | Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) | Inertsil C8-3 |
| LB264 | Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) | Inertsil C8-3 |
| LB265 | Analysis of Tacrolimus (Under the Condition of the Japanese Pharmacopoeia, Tacrolimus Capsules) | Inertsil ODS-2 |
| LB267 | Analysis of D-Mannitol (Under the Condition of the Japanese Pharmacopoeia, D-Mannitol) | HC-75(Ca+) |
| LB268 | Analysis of Tetracyclines (InertSustain C18) | InertSustain C18 |
| LB269 | Analysis of Tetracyclines (InertSustainSwift C18) | InertSustainSwift C18 |
| LB270 | Analysis of β-blocker | InertSustainSwift C18 |
| LB271 | Analysis of Tulathromycin | InertSustainSwift C18 |
| LB272 | Analysis of Ibuprofen and Indometacin | InertSustain Phenylhexyl |
| LB273 | Analysis of Vitamin B | InertSustain Phenylhexyl |
| LB274 | Analysis of Capsaicin | InertSustain Phenylhexyl |
| LB275 | Analysis of Histamine antagonist | InertSustain Phenylhexyl |
| LB276 | Analysis of Anti-depressant drugs | InertSustain Phenylhexyl |
| LB277 | Analysis of β-blocker | InertSustain Phenylhexyl |
| LB278 | Analysis of Calcium antagonist | InertSustain Phenylhexyl |
| LB279 | Analysis of Indometacin (Under the Condition of European Pharmacopoeia 8.2) | InertSustain Phenylhexyl |
| LB281 | Analysis of Montelukast sodium (Inertsil Ph) (Under the Condition of the Japanese Pharmacopoeia, Montelukast sodium Tablets) | Inertsil Ph |
| LB282 | Analysis of Povidone (Under the Condition of the Japanese Pharmacopoeia 16th edition, (4) 1-Vinyl-2-pyrrolidone) | InertSustain C8 |
| LB283 | Analysis of Silodosin (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB284 | Analysis of Silodosin (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB285 | Analysis of Ribavirin (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-4 HP |
| LB286 | Analysis of Ribavirin (Under the Condition of the Japanese Pharmacopoeia) | Inertsil ODS-4 HP |
| LB287 | Analysis of Sugar Spheres (Under the Condition of USP 37-NF32) | Inertsil NH2 |
| LB289 | Analysis of Aflatoxin | InertSustain C18 |
| LB290 | Analysis of Cefalexin (Under the Condition of the Japanese Pharmacopoeia, Cefalexin Combination Granules) | InertSustain C18 |
| LB291 | Analysis of Ticlopidine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Ticlopidine hydrochloride Tablets) | InertSustain C18 |
| LB294 | Analysis of Montelukast sodium | InertSustain Phenylhexyl |
| LB295 | Analysis of Irbesartan (Under the Condition of the Japanese Pharmacopoeia) | InertSustain C18 |
| LB297 | Peptide Separation of Casein Tryptic Digests by Preparative HPLC ODS Column (20 mm I.D.) | Inertsil ODS-3 |
| LB298 | Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia) | Inertsil WP300 C18 |
| LB299 | Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil ODS-3 |
| LB300 | Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) | Inertsil WP300 C18 |